Crohn's Disease

RedHill’s RHB-104 hits primary endpoint in Crohn’s phase 3
RedHill’s RHB-104 hits primary endpoint in Crohn’s phase 3
Fierce Biotech
Redhill Biopharma
clinical trials
Crohn's Disease
RHB-104
Flag link:
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Fierce Pharma
JNJ
Tremfya
MorphoSys
Janssen
Crohn's Disease
clinical trials
Flag link:
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
Yahoo/Zacks.com
AbbVie
Upadacitinib
Crohn's Disease
Flag link:
J&J strikes potential $1B JAK inhibitor deal with Theravance
J&J strikes potential $1B JAK inhibitor deal with Theravance
Biopharma Dive
JNJ
JAK inhibitors
Theravance
TD-1473
drug development
Crohn's Disease
ulcerative colitis
Flag link:
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
Yahoo/Reuters
Pfizer
biosimilars
JNJ
Remicade
Ifixi
rheumatoid arthritis
Crohn's Disease
Flag link:
Price Hikes Insulate Celgene From a Failure
Price Hikes Insulate Celgene From a Failure
Motley Fool
Celgene
drug pricing
GED-301
Crohn's Disease
Flag link:
With help from J&J, upstart Provention lands rights to two mid-stage IBD drugs and shoots for PhII
With help from J&J, upstart Provention lands rights to two mid-stage IBD drugs and shoots for PhII
Endpoints
JNJ
Provention Bio
IBD
inflammatory bowel disease
PRV-6527
Crohn's Disease
PRV-300
ulcerative colitis
Flag link:
Johnson & Johnson shows off under-pressure Stelara's latest indication—Crohn's—in new DTC spot
Johnson & Johnson shows off under-pressure Stelara's latest indication—Crohn's—in new DTC spot
Fierce Pharma
JNJ
Stelara
Crohn's Disease
drug advertising
DTC ads
Flag link:
Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug
Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug
Fierce Biotech
JNJ
Protagonist Therapeutics
M&A
Crohn's Disease
PTG-200
Flag link:
AbbVie's JAK-1 inhibitor hits the mark in Crohn's disease
AbbVie's JAK-1 inhibitor hits the mark in Crohn's disease
BioPharma Dive
AbbVie
JAK inhibitors
Crohn's Disease
Upadacitinib
Flag link:
Pfizer and Celltrion Seek Biosimilar Interchangeability for Crohn’s Disease Drug
Pfizer and Celltrion Seek Biosimilar Interchangeability for Crohn’s Disease Drug
Xtalks
Pfizer
Celltrion
biosimilars
Crohn's Disease
Inflectra
Remicade
Flag link:
Takeda, TiGenix stem cell therapy shows sustained effect
Takeda, TiGenix stem cell therapy shows sustained effect
Fierce Biotech
Takeda
TiGenix
stem cells
Cx601
Crohn's Disease
Flag link:
Gilead Takes Lead on Crohn's over AbbVie
Gilead Takes Lead on Crohn's over AbbVie
Investopedia
Gilead Sciences
AbbVie
Crohn's Disease
Galapagos
filgotinib
ABT-494
Flag link:
Celgene Skips the Placebo, Fails Drug Development 101
Celgene Skips the Placebo, Fails Drug Development 101
TheStreet.com
Celgene
drug development
clinical trials
placebo
GED-0301
Crohn's Disease
Flag link:
Celgene Crohn's Pill Data Unspectacular but Perhaps Good Enough
Celgene Crohn's Pill Data Unspectacular but Perhaps Good Enough
TheStreet.com
Celgene
Crohn's Disease
GED-0301
Flag link:
Could J&J's recent news about its rheumatoid arthritis and Crohn's disease drugs threaten AbbVie's Humira?
Could J&J's recent news about its rheumatoid arthritis and Crohn's disease drugs threaten AbbVie's Humira?
Motley Fool
JNJ
rheumatoid arthritis
Crohn's Disease
AbbVie
Humira
sirukumab
Flag link:
AstraZeneca hands off another Amgen-partnered drug in a $1.5B deal with an acquisitive Allergan
AstraZeneca hands off another Amgen-partnered drug in a $1.5B deal with an acquisitive Allergan
Endpoints
AstraZeneca
Amgen
Allergan
MEDI2070
ulcerative colitis
Crohn's Disease
Flag link:
Will Gilead (GILD) Stock Be Helped by Positive Crohn's Drug Results?
Will Gilead (GILD) Stock Be Helped by Positive Crohn's Drug Results?
TheStreet.com
Gilead Sciences
Crohn's Disease
filgotinib
Galapagos
Flag link:
Celgene’s update on its big Crohn’s drug? Trust us, we’re doing fine
Celgene’s update on its big Crohn’s drug? Trust us, we’re doing fine
Endpoints
Celgene
Crohn's Disease
GED-0301
Flag link:
How AbbVie Expects Risankizumab to Be a Transformative Therapy
How AbbVie Expects Risankizumab to Be a Transformative Therapy
Market Realist
AbbVie
risankizumab
Crohn's Disease
Flag link:

Pages